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ABSTRAK
Tujuan: untuk mengetahui pengaruh penggunaan obat tuberkulosis rifampisin terhadap kadar plasma efavirenz 
dan viral load pasien HIV/AIDS-Tuberkulosis yang telah mendapat terapi antiretrovirus 3-6 bulan. Metode: kadar 
efavirenz dan viral load pasien HIV/AIDS yang telah mendapat terapi antiretroviral berbasis efavirenz dosis 600 
mg/hari selama 3-6 bulan terapi dan pasien HIV/AIDS-Tuberkulosis dengan terapi antiretroviral yang sama 
ditambah terapi antituberkulosis berbasis rifampisin di RSPI Prof. DR Sulianti Saroso dalam periode Februari-
Mei 2015 diukur. Kadar efavirenz pada kedua kelompok dibandingkan dengan menggunakan uji Mann-Whitney, 
sedangkan proporsi pasien dengan viral load >40 kopi/mL dianalisis dengan uji kai kuadrat. Hasil: dari 45 pasien 
(27 dengan HIV/AIDS dan 18 dengan infeksi HIV/AIDS-tuberkulosis). Median konsentrasi plasma efavirenz pada 
kelompok HIV/AIDS 0,680 mg/L (range 0,24-5,67 mg/L) dan pada kelompok HIV/AIDS-tuberkulosis 0,685 mg/L 
(range 0,12-2,23 mg/L tidak berbeda bermakna antara kedua kelompok. Proporsi pasien dengan viral load ≥40 
kopi/mL setelah 3-6 bulan pengobatan ARV pada kelompok HIV/AIDS 51,9%, dan kelompok HIV/AIDS-tuberkulosis 
72,2% juga tidak berbeda bermakna (uji kai kuadrat, p=0,291). Kesimpulan: kadar plasma efavirenz pada pasien 
HIV/AIDS–tuberkulosis yang mendapat antiretroviral dan rifampisin tidak berbeda bermakna dengan pasien HIV/
AIDS tanpa tuberkulosis. Proporsi pasien dengan viral load >40 kopi/mL lebih tinggi pada pasien yang mendapat 
antiretroviral dan rifampisin dibandingkan dengan pasien yang tidak mendapat rifampisin, namun secara statistik 
perbedaan ini tidak bermakna. Diperlukan penelitian dengan jumlah pasien yang lebih besar untuk klarifikasi 
pengaruh rifampisin terhadap kadar plasma eavirenz dan terhadap viral load.
Kata kunci: HIV, tuberkulosis, efavirenz, rifampisin, viral load.
ABSTRACT
Aim: to determine the effect of a rifampicin-containing tuberculosis regimen on efavirenz plasma concentrations 
and viral load in HIV/AIDS-Tuberculosis infection patients who received efavirenz-based antiretroviral therapy. 
Methods: plasma efavirenz concentrations and HIV viral load were measured in HIV/AIDS patients treated with 
600 mg efavirenz-based antiretroviral for 3 to 6 months and in HIV/AIDS-Tuberculosis infection patients treated 
with similar antiretroviral regimen plus rifampicin-containing antituberculosis in Sulianti Saroso Infectious disease 
Hospital, Jakarta. Plasma efavirenz concentration in both groups were compared using Mann-Whitney test, while 
proportion of patients with viral load >40 copy/mL were analyzed with chi-square test. Results: forty five patients 
(27 with HIV/AIDS and 18 with HIV/AIDS-Tuberculosis infections) were recruited during the period of February 
to May 2015. The median efavirenz plasma concentration obtained from HIV/AIDS group was 0,680 mg/L(range 
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0,24 to 5,67 mg/L and that obtained from HIV/AIDS-Tuberculosis group was 0.685 mg/L (0.12 -2.23 mg/L) which 
was not significantly different statistically. The proportion of patients with viral load ≥40 copies/mL after 3-6 months 
of ARV treatment in the HIV/AIDS group was 51.9%, and in the HIV/AIDS-Tuberculosis group was 72.2%, which 
was not significantly different statistically (Chi Square test, p=0.291). Conclusion: plasma efavirenz concentration 
in HIV/AIDS-tuberculosis patients receiving antiretroviral and rifampicin is not significantly different from that 
on HIV/AIDS patients without tuberculosis. Proportion of patients with viral load of >40 copy/mL is higher in 
HIV/AIDS-tuberculosis patients receiving rifampicin compared to HIV/AIDS patients that not receive rifampicin. 
However, this difference did not reach statistical significance. Confirmatory studies with bigger sample size are 
needed to clarify the influence of rifampicin on plasma level of efavirenzand and on viral load.
Keywords: HIV, tuberculosis, rifampicin, efavirenz, viral load.
INTRODUCTION
Efavirenz is metabolized by the enzyme 
cytochrome P-450 (CYP), i.e. the CYP2B6 and 
CYP3A4 isozymes, of which rifampicin is an 
inducer. Earlier studies in the white population 
and in healthy volunteers reported that rifampicin 
coadministration decreases plasma levels of 
efavirenz. The therapeutic range of efavirenz 
was considered to be 1-4 mg/L, as previously 
reported. Sub-therapeutic drug concentrations 
may increase the risk of drug resistance and 
treatment failure. Otherwise, studies from 
diverse populations, mainly in black and Asian 
populations, reported no effect of rifampicin on 
efavirenz plasma concentration or the increase 
in efavirenz plasma concentration during 
rifampicin-based anti-TB treatment.1-3 However, 
studies that prove the impact of rifampicin co-
administration on efavirenz-based antiretroviral 
therapy outcome is understudied.3
Monitoring the efficacy of antiretroviral 
treatment is generally done after 6 months. 
Routine virologic monitoring (viral load 
measurement every 3-6 months) has been the 
standard of care for earlier detection of treatment 
failure in many middle and high-income 
nations.3,4
US Food and Drug administration (FDA) 
approved to increase the dose of efavirenz 
from 600 to 800 mg/day when coadministrared 
with rifampicin in patients with pretreatment 
bodyweight of >50 kg.2 However, the appropriate 
dose of efavirenz during rifampicin-based 
tuberculosis treatment remains debated.3,5 On the 
other hand, concentrations above the therapeutic 
range may increase drug related toxicities, such 
as neuropsychiatric side effects, which may 
lead to the emergence of resistance resulting 
from treatment interruptions.6 Administration of 
standard doses of efavirenz results in significant 
variations in plasma drug concentrations between 
populations. The reasons for the large inter-
individual variability of efavirenz concentration 
are multifactorial, and involve ethnicity or 
CYP2B6 pharmacogenetic variations and drug-
drug interactions.7
In this study, we aimed to determine the 
effect of rifampicin-containing tuberculosis 
regimen on efavirenz plasma concentrations and 
viral load in HIV/AIDS-TB infection patients 
who have received efavirenz-based antiretroviral 
therapy for 3 to 6 months.
METHODS
Plasma efavirenz concentrations and HIV 
viral load were measured in HIV/AIDS patients 
treated with 600 mg efavirenz-based antiretroviral 
for 3 to 6 months and in HIV/AIDS-TB infection, 
patients treated with similar antiretroviral regimen 
plus rifampicin-containing antituberculosis in 
Sulianti Saroso Infectious Disease Hospital, 
Jakarta, during the period of February to May 
2015, and the results were compared.The 
estimated sample size was 52 patients consisted 
of 26 groups of HIV/AIDS and 26 groups of HIV/
AIDS-TB. Poor adherence was defined as a value 
of pill consumption <95% pills, and patients with 
poor adherence were excluded.
Blood samples were collected early in the 
morning on EDTA tubes 14 ± 2 hours after 
efavirenz intake. After centrifugation, plasma 
was transferred and stored at -80ºC until 
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analysis.The plasma concentrationsof efavirenz 
were determined using High Performance Liquid 
Chromatography (HPLC) method with UV 
detection at Pharma Metric laboratories. Viral 
load was measured using Polymerase Chain 
Reaction (PCR) method in referral laboratories 
at Sulianti Saroso Infectious Disease Hospital, 
Jakarta.
Efavirenz plasma concentrations between 
HIV/AIDS group and HIV/AIDS-TB group 
were compared  using Mann-Whitney U test, and 
proportional data was analysed using Chi Square 
tests. All statistical analyses were performed 
using SPSS program version 14.
RESULTS
During the study periode, only 45 patients 
(27 with HIV/AIDS and 18 with HIV/AIDS-TB 
infections) were recruited in accordance with the 
inclusion and exclusion criterias due to limited 
patients availability. Characteristic and clinical 
profile of the 45 patients are shown in Table 1 
and Table 2.
The median efavirenz plasma concentration 
obtained from HIV/AIDS group was 0.680 mg/L 
(range 0.24 to 5.67 mg/L) and that obtained 
from HIV/AIDS-TB group was 0.685 mg/L 
(range 0.12-2.23 mg/L). Statistically they were 
not significantly different (Mann-Whitney U 
test, p=0.480). Table 3 shows the proportion 
of patients with sub-therapeutic efavirenz 
plasma concentration (<1 mg/L) in the HIV/
AIDS group and HIV/AIDS-TB group. There 
was no significant difference (chi square, 
p=0.948) between the proportion of patients with 





Sex (male), n (%) 22 (81.48) 14 (77.78)
Age (years), median 
(range) 32 (22-38) 32 (24-45)
Weigth (kg), median 
(range) 64 (45-86) 54 (44-69)
Heigth (cm), median 
(range) 170 (150-181) 160 (147-175)
Body mass index, n (%)
 - <18.5 1 (3.70) 4 (22.2)
 - >18.5 26 (96.3) 14 (77.8)





Baseline CD4 counts, n (%)
 - <350 sel/mL 21 (77.8) 18 (100.0)
 - >350 sel/mL 6 (22.2) 0 (0.0)
WHO staging, n (%)
 - Stage I/II 22 (81.5) 0 (0.0)
 - Stage III/IV 5 (18.5) 18 (100.0)
ART, n (%)
 - AZT+3TC+EFV 3 (11.1) 7 (38.9)
 - TDF+3TC+EFV 17 (62.9) 8 (44.5)
 - TDF+FTC+EFV 7 (25.9) 3 (16.7)
Rifampicin 450/INH 0 (0.0) 16 (88.8)
Rifampicin 600/INH 0 (0.0) 2 (11.12)
Oral candidiasis 4 (14.8) 10 (55.6)
Hepatitis B 0 (0.0) 1 (5.56)
Hepatitis C 0 (0.0) 1 (5.56)
Toxoplasmosis 0 (0.0) 1 (5.56)
Table 3. The proportion of patients with sub-therapeutic 
efavirenz plasma concentration (<1 mg/L) in the HIV/AIDS 







(n=27) 18 (66.7) 9 (33.3)
HIV/AIDS-TB 
group (n=18) 13 (72.2) 5 (27.8)
Chi Square test, p=0,948
* Two of 9 patients from HIV/AIDS group  had efavirenz 
plasma concentration  ≥ 4 mg/L (supratherapeutic) ie 
5,34 mg/L and 5,67 mg/L
subtherapeutic efavirenz plasma concentration in 
the groups.
In total, only 7 out of 45 patients (15.6%) 
had viral load values ranged from 54,800 to over 
1,000,000 copies/ml before ARV therapy. Figure 
1 showed a comparison of viral load before and 
after 3-6 months of ARV therapy in 7 patients.
In a total of 45 patients, the proportion of 
patients with successful virological suppression 
(viral load <40 copies/ml) after 3-6 months of 
ARV therapy were 48.1% in HIV/AIDS group 
and 27.8% in HIV/AIDS-TB group. Viral load 
≥40 copies/ml were seen in the HIV/AIDS group 
(51,9%), and in HIV/AIDS-TB group (72.2%), 
including the 3 patients (6.67%) in HIV/AIDS-TB 
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shows a comparison between efavirenz plasma 
concentration and viral load in the groups.
In a total of 45 patients, 35 (77.78%) had 
adverse effects.Efavirenz has been related 
to CNS effect. Nineteen (70.3%) had central 
nervous system (CNS) side effects. One 
of 2 patients in the HIV/AIDS group with 
supratherapeutic efavirenz plasma concentration 
(5.67 mg/L) had CNS side effects. Generally, 
some patients experienced more than one side 
effects (Table 5). Side effects usually occurs 
within the first few weeks of treatment.
Table 4. Viral load after 3-6 months of ARV therapy in 






<40 copies/mL 13 (48.1) 5 (27.8)
>40 copies/mL 14 (51.9) 13 (72.2)

















Sub-therapeutic Therapeutic Sub-therapeutic Therapeutic
HIV HIV/TB
Figure 2. Comparison between efavirenz plasma concentration and viral load in the groups.
group that have viral load >1000 copies/ml. (Table 
4) There was no significant difference (Chi square, 
p = 0.291) between the patient with viral load <40 
copies/ml and ≥40 copies/ml in those 2 groups.
Among the 18 patients in the HIV/AIDS-
TB group, 4 (30.8%) had viral load <40 copies/
ml with sub-therapeutic efavirenz plasma 
concentration after 3-6 months of ARV therapy. 
Among the 27 in the HIV/AIDS group, 10 
(55.6%) had viral load <40 copies/ml with 
sub-therapeutic efavirenz plasma concentration 
after 3-6 months of ARV therapy. Figure 2 





CNS effect, n (%) 19 (70.3) 10 (55.6)
 - dizziness 6 4
 - halusination 2 2
 - insomnia 3 4
 - headache 2 4
 - nightmares 3 2
 - somnolence 5 -
 - dementia 1 -
Hepatotoxicity, n (%) 1 (3.70) 3 (16.7)
Gastrointestinal 
effect, n (%)
8 (29.6) 3 (16.7)
 - nausea vomitus 8 3
 - diarrhea 
(dehydration) 1 -
 - constipation 1 -
Skin effect, n (%) 4 (14.8) 4 (22.2)








Figure 1. comparison of viral Load before and after 3-6 
months of ARV therapy in 7 patients from HIV/AIDS and 
HIV/AIDS-TB group
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DISCUSION
Our results show that after administration 
of a daily dose of 600 mg efavirenz-based 
antiretroviral therapy for 3-6 months, efavirenz 
plasma concentrations were not significantly 
different between group of HIV/AIDS-TB 
patients receiving anti-TB therapy and HIV/
AIDS patients receiving efavirenz-based therapy 
only. Yenny et al studied the pharmacokinetics 
effect of rifampicin on plasma efavirenz 
concentrations in healthy volunteers and reported 
that rifampicin reduced efavirenz’s AUC by 
20.4%.9 Other studies have been conducted to 
assess the effect of rifampicin or rifampicin 
based tuberculosis treatment co-administration 
on efavirenz concentrations, which reported 
results different from our report here.10,11
Our results  are in agreement with 
several studies from Sub-Saharan Africa and 
Cambodia.2,3,12 Those studies concluded that 
efavirenz plasma concentrations were not 
significantly different between group of HIV/
AIDS-TB patients and group of HIV/AIDS 
patients who received efavirenz-based only.
Efavirenz plasma exposure is mainly 
influenced by CYP2B6 genotype.2 The common 
clinical practice of administering the same dose 
to all patients leads to profound differences in 
drug plasma concentration, which is correlated 
with patient genotype. Several polymorphisms 
in the gene CYP2B6 may influence isoenzyme 
activity and therefore the hepatic metabolism 
and clearance of efavirenz.14 Efavirenz are 
primarily metabolized by hepatic CYP2B6, with 
some contributions from CYP3A4. Differences 
in various studies show that there is a dominant 
activity of CYP2B6 over CYP3A4 in various 
populations.9
Identification of slow and extensive 
metabolizers for the category of drugs 
metabolized by CYP2B6 is important for 
understanding the differences in efavirenz 
plasma concentrations and in clinical response of 
drugs metabolized by this enzyme. The patients 
with an extensive metabolizer genotype, causing 
a subtherapeutic efavirenz plasma concentration. 
The patients with a slow metabolizer genotype 
predicted to increase efavirenz concentrations.8,14 
We observed a large proportion of patients with 
sub-therapeutic efavirenz concentrations in HIV/
AIDS group (66.7%) and in HIV/AIDS-TB 
group (72.2%). One of the plausible reasons is 
the dominant activity of extensive metabolizer 
genotype. Even though, in Indonesia, no studies 
have identified the CYP2B6enzyme activity.
Extensive rifampisin-efavirenz interaction 
studies evaluated not only the effect on 
efavirenz concentration, but also its effecton 
HIV antiretroviral treatment outcome.3 Overall, 
our results show differences in virologic 
suppression after 3-6 months ARV therapy 
between the HIV/AIDS-TB group and the HIV/
AIDS group; indicating that it takes longer time 
to reach virology success during dual TB–HIV 
co-infection as compared to HIV-only infection, 
but there was no significant difference (p=0.291) 
between the proportions of patients with viral 
load <40 copies/mL and ≥40 copies/mL in the 
groups. This non-significancy might be due to 
the small number of patients included in this 
study, a larger study is needed to see whether 
the differences is indeed true.
In total, there was no significant difference 
between the proportion of patients with 
subtherapeutic efavirenz plasma concentration 
in the groups with viral load <40 copies/mL 
and ≥40 copies/mL. This may indicate that 
after administration of a daily dose of 600 
mg efavirenz-based antiretroviral therapy 
for 3-6 months in the groups, although with 
subtherapeutic efavirenz concentration, overall, 
virological response was still good. In our report, 
three patients in the HIV/AIDS-TB group with 
sub-therapeutic efavirenz concentration had 
viral load >1,000 copies/mL. Virologic failure 
was defined as a viral load of >1,000 copies/
mL, but to detect early treatment failure, having 
two viral load monitorings within the first year, 
would be ideal.8 Only 1 out of 3 patients had 
two viral load monitoring, i.e viral load 185.758 
copies/mL to 81.954 copies/mL, and after ARV 
initiation has shown significant improvement of 
virologic outcomes.
In our study, the proportion of patients with 
CNS side-effects in the HIV/AIDS group was 
70.3% and in the HIV/AIDS-TB group was 
55.6%. The cause of CNS side-effects probably 
was efavirenz high lipophilic nature, its easily 
Vol 48 • Number 1 • January 2016                  Efavirenz plasma concentrations and HIV viral load in HIV/AIDS
15
penetrates the blood brain barier. Although 
most patients’ plasma efavirenz concentrations 
are sub-therapeutic, efavirenz was known to be 
distributed in the cerebrospinal fluid at 0.26% 
to 1.19% from the concentrations of efavirenz 
in plasma.15
Based on efficacy data, in terms of virologic 
response, obtained in this study; as well as the 
fairly high incidence of CNS side effects, the 
recommended increase in the dose of efavirenz 
from 600 mg/day to 800 mg/day in patients with 
HIV/AIDS-TB receiving rifampicin seems not 
necessary. On the other hand, it had been shown 
that the provision of antiretroviral therapy along 
with antituberculosis in patients with HIV/
AIDS-TB had no drug interaction, so it might 
be better to treat both diseases simultaneously 
than to delay therapy.
The limitation of our study is that the sample 
size was small (27 with HIV/AIDS and 18 with 
HIV/AIDS-TB infections). The sample of HIV/
TB did not reach the minimum target, so our 
study was not adequately powered to detect 
the differences. Some other things need to be 
investigated, such as the cause of subtherapeutic 
efavirenz concentrations, however, these 
concentration still show therapeutic efficacy in 
terms of viral count, as well as high numbers of 
side effects. Does it mean that our dosage is too 
high for Indonesians?
CONCLUSION
Plasma efavirenz concentrat ion in 
HIV/AIDS-tuberculosis patients receiving 
antiretroviral and rifampicin is not significantly 
different from those with HIV/AIDS without 
tuberculosis. Proportion of patients with viral 
load of >40 copy/mL is higher in HIV/AIDS-
tuberculosis patients receiving rifampicin 
compared to HIV/AIDS patients that not receive 
rifampicin. However, this difference did not 
reach statistical significance. Confirmatory 
studies with bigger sample size are needed to 
clarify the influence of rifampicin on plasma 
level of efavirenz and on viral load.
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